Evaluation of Bleeding Risk in Patients Exposed to Therapeutic Unfractionated or Low-Molecular-Weight Heparin: A Cohort Study in the Context of a Quality Improvement Initiative

被引:50
作者
Cossette, Benoit [1 ,2 ]
Pelletier, Marie-Eve [3 ]
Carrier, Nathalie [4 ]
Turgeon, Martin [1 ]
Leclair, Christian [1 ]
Charron, Pierre [3 ]
Echenberg, Donald [3 ]
Fayad, Tania [3 ]
Farand, Paul [3 ]
机构
[1] CHU Sherbrooke, Dept Pharm, Sherbrooke, PQ J1H 5N4, Canada
[2] CHU Sherbrooke, Hlth Technol Assessment Unit, Sherbrooke, PQ J1H 5N4, Canada
[3] Univ Sherbrooke, Dept Med, Sherbrooke, PQ J1K 2R1, Canada
[4] CHU Sherbrooke, Ctr Rech Clin Etienne Le Bei, Sherbrooke, PQ J1H 5N4, Canada
关键词
adverse drug events; bleeding; hemorrhage; heparin; low-molecular-weight heparin; PARTIAL THROMBOPLASTIN TIME; ACUTE CORONARY SYNDROMES; ADVERSE DRUG EVENTS; HOSPITALIZED-PATIENTS; ANTICOAGULANT; COMPLICATIONS;
D O I
10.1345/aph.1M615
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Bleeding associated with the use of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) can be a serious complication of health-care management and should be the focus of quality improvement initiatives by institutions. OBJECTIVE: To measure the incidence of bleeding with UFH and LMWH and evaluate associated risk factors. METHODS: An observational cohort study was conducted at a secondary and tertiary care hospital in Canada. All adults receiving therapeutic doses of UFH or LMWH between April 2006 and March 2007, with the exception of cardiac surgery patients, were included. Bleeding episodes were classified per the GUSTO scale. RESULTS: Of 3066 hospitalizations, the incidence of moderate or severe bleeding was 3.5%. Advanced age (OR 1.02, 95% CI 1.01 to 1.04; p < 0.001), female sex (OR 1.80, 95% CI 1.21 to 2.66; p = 0.003), UFH instead of LMWH (OR 4.72, 95% CI 2.17 to 10.30; p < 0.001), creatinine clearance (CrCI) (OR 0.89, 95% Cl 0.84 to 0.95; p < 0.001, for a difference of 10 mL/min in CrCI), and supratherapeutic activated partial thromboplastin time (aPTT) (OR 3.88, 95% Cl 2.25 to 6.69; p < 0.001 for >180 vs <90 seconds) were associated with a higher risk of bleeding in univariate analysis. In a multivariate model without aPTT, CrCI (OR 0.90, 95% CI 0.85 to 0.96; p < 0.001, for a difference of 10 mL/min in CrCI) and UFH (OR 2.35, 95% CI 1.11 to 4.98; p = 0.005) were significant predictors of bleeding. Among the bleeding episodes, 31% were in a postoperative context and 15% were following a puncture. CONCLUSIONS: Our findings show that CrCI and aPTT values, as well as the type of heparin used, are significant predictors of bleeding in patients receiving UFH or LMWH and that dosages should be adjusted to patient weight. The reason for all supratherapeutic aPTT levels should be sought and corrective measures taken immediately.
引用
收藏
页码:994 / 1002
页数:9
相关论文
共 29 条
[11]   Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes [J].
Harrington, Robert A. ;
Becker, Richard C. ;
Cannon, Christopher P. ;
Gutterman, David ;
Lincoff, A. Michael ;
Popma, Jeffrey J. ;
Steg, Gabriel ;
Guyatt, Gordon H. ;
Goodman, Shaun G. .
CHEST, 2008, 133 (06) :670S-707S
[12]   OPTIMAL THERAPEUTIC LEVEL OF HEPARIN-THERAPY IN PATIENTS WITH VENOUS THROMBOSIS [J].
HULL, RD ;
RASKOB, GE ;
ROSENBLOOM, D ;
LEMAIRE, J ;
PINEO, GF ;
BAYLIS, B ;
GINSBERG, JS ;
PANJU, AA ;
BRILLEDWARDS, P ;
BRANT, R .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (08) :1589-1595
[13]   Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis [J].
Hylek, EM ;
Regan, S ;
Henault, LE ;
Gardner, M ;
Chan, AT ;
Singer, DE ;
Barry, MJ .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :621-627
[14]  
*I SAF MED PRACT, LIST HIGH AL MED
[15]  
*JOINT COMM, NAT PAT SAF GOALS HO
[16]   Antithrombotic therapy for venous thromboembolic disease [J].
Kearon, Clive ;
Kahn, Susan R. ;
Agnelli, Giancarlo ;
Goldhaber, Samuel ;
Raskob, Gary E. ;
Comerota, Anthony J. .
CHEST, 2008, 133 (06) :454S-545S
[17]   Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism [J].
Kearon, Clive ;
Ginsberg, Jeffrey S. ;
Julian, Jim A. ;
Douketis, James ;
Solymoss, Susan ;
Ockelford, Paul ;
Jackson, Sharon ;
Turpie, Alexander G. ;
MacKinnon, Betsy ;
Hirsh, Jack ;
Gent, Michael .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (08) :935-942
[18]   THE NATURE OF ADVERSE EVENTS IN HOSPITALIZED-PATIENTS - RESULTS OF THE HARVARD MEDICAL-PRACTICE STUDY-II [J].
LEAPE, LL ;
BRENNAN, TA ;
LAIRD, N ;
LAWTHERS, AG ;
LOCALIO, AR ;
BARNES, BA ;
HEBERT, L ;
NEWHOUSE, JP ;
WEILER, PC ;
HIATT, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (06) :377-384
[19]   The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: A review of GUSTO-IIb [J].
Lee, MS ;
Wali, AU ;
Menon, V ;
Berkowitz, SD ;
Thompson, TD ;
Califf, RM ;
Topol, EJ ;
Granger, CB ;
Hochman, JS .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2002, 14 (02) :91-101
[20]   BLEEDING TENDENCY IN UREMIA [J].
LEWIS, JH ;
ZUCKER, MB ;
FERGUSON, JH .
BLOOD, 1956, 11 (12) :1073-1076